Navidea Biopharma (NAVB) Misses Q2 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.24 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood prices $2B convertible notes offering due 2029
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates